Search Results

You are looking at 1 - 10 of 25 items for :

  • "medullary thyroid cancer" x
  • Refine by Access: All x
Clear All
Full access

Stephanie A. Terezakis and Nancy Y. Lee

Figure 1 Axial CT scan identifying a locally advanced thyroid mass with tracheal deviation. A fine needle aspiration performed identified medullary thyroid cancer. Surgical Considerations Surgical resection for both familial and

Full access

Jennifer B. Ogilvie and Electron Kebebew

lymph node dissection in sporadic and hereditary medullary thyroid cancer . J Clin Endocrinol Metab 2003 ; 88 : 2070 – 2075 . 8. Quayle FJ Moley JF . Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes . J Surg Oncol 2005

Full access

Robert I. Haddad

“These are exciting times in thyroid cancer. Two new drugs have become available for advanced medullary thyroid cancer, and more are expected in the next few years,” said Robert I. Haddad, MD, Associate Professor of Medicine at Harvard Medical

Full access

R. Michael Tuttle, Douglas W. Ball, David Byrd, Gilbert H. Daniels, Raza A. Dilawari, Gerard M. Doherty, Quan-Yang Duh, Hormoz Ehya, William B. Farrar, Robert I. Haddad, Fouad Kandeel, Richard T. Kloos, Peter Kopp, Dominick M. Lamonica, Thom R. Loree, William M. Lydiatt, Judith McCaffrey, John A. Olson Jr., Lee Parks, John A. Ridge, Jatin P. Shah, Steven I. Sherman, Cord Sturgeon, Steven G. Waguespack, Thomas N. Wang, and Lori J. Wirth

. Kloos RT Eng C Evans DB . Medullary thyroid cancer: management guidelines of the American Thyroid Association . Thyroid 2009 ; 19 : 565 – 612 . 3. Gagel RF Hoff AO Cote GJ . Medullary thyroid carcinoma . In: Braverman LE, Utiger RD, eds

Full access

Jeffrey F. Moley

justified? Surgery 1997 ; 122 : 1124 – 1130 ; discussion 30–31 . 8. Moley JF Wells SA Dilley WG Tisell LE . Reoperation for recurrent or persistent medullary thyroid cancer . Surgery 1993 ; 114 : 1090 – 1095 ; discussion 1095

Full access

Elizabeth G. Grubbs and Douglas B. Evans

. Surgery 2001 ; 130 : 1044 – 1049 . 39. Evans DB Shapiro SE Cote GJ . Invited commentary: medullary thyroid cancer: the importance of RET testing . Surgery 2007 ; 141 : 96 – 99 . 40. Brandi ML Gagel RF Angeli A . Guidelines for

Full access

Sriman Swarup, Anita Sultan, Nusrat Jahan, Upama Sharma, Nimesh Adhikari, Yin M. Myat, Ye Aung, Myo H. Zaw, and Kyaw Z. Thein

,703 patients with medullary thyroid cancer, prostate cancer, renal cell carcinoma, and hepatocellular carcinoma were eligible. Studies comparing cabozantinib (C) vs everolimus, C vs placebo, C vs prednisone were included in the analysis. The relative risks of

Full access

R. Michael Tuttle, Douglas W. Ball, David Byrd, Raza A. Dilawari, Gerard M. Doherty, Quan-Yang Duh, Hormoz Ehya, William B. Farrar, Robert I. Haddad, Fouad Kandeel, Richard T. Kloos, Peter Kopp, Dominick M. Lamonica, Thom R. Loree, William M. Lydiatt, Judith C. McCaffrey, John A. Olson Jr., Lee Parks, John A. Ridge, Jatin P. Shah, Steven I. Sherman, Cord Sturgeon, Steven G. Waguespack, Thomas N. Wang, and Lori J. Wirth

) evidence of other thyroid cancer–associated diseases or syndromes, such as hyperparathyroidism, pheochromocytoma, marfanoid habitus, and mucosal neuromas (MEN2B), which make the presence of medullary thyroid cancer more likely; or 4) the presence of

Full access

R. Michael Tuttle, Robert I. Haddad, Douglas W. Ball, David Byrd, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, William M. Lydiatt, Judith McCaffrey, Jeffrey F. Moley, Lee Parks, Christopher D. Raeburn, John A. Ridge, Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Steven I. Sherman, Cord Sturgeon, Steven G. Waguespack, Thomas N. Wang, Lori J. Wirth, Karin G. Hoffmann, and Miranda Hughes

. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer . N Engl J Med 2013 ; 368 : 623 – 632 . 21 Bales SR Chopra IJ . Targeted treatment of differentiated and medullary thyroid cancer . J Thyroid Res 2011 ; 2011 : 102636

Full access

Robert I Haddad, Lindsay Bischoff, Douglas Ball, Victor Bernet, Erik Blomain, Naifa Lamki Busaidy, Michael Campbell, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Whitney S. Goldner, Theresa Guo, Megan Haymart, Shelby Holt, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Dominick M. Lamonica, Susan Mandel, Stephanie Markovina, Bryan McIver, Christopher D. Raeburn, Rod Rezaee, John A. Ridge, Mara Y. Roth, Randall P. Scheri, Jatin P. Shah, Jennifer A. Sipos, Rebecca Sippel, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Richard J. Wong, Michael Yeh, Carly J. Cassara, and Susan Darlow

was not statistically significant (stratified HR, 0.85; 95% CI, 0.64–1.12, P =.24). 117 Exploratory analyses have suggested that cabozantinib may have a greater clinical benefit for medullary thyroid cancers harboring RET M918T or RAS mutations